Zevra Therapeutics Reports Q3 2026 Revenue Growth Driven by MIPLYFFA
Zevra Therapeutics (ZVRA) reported strong third-quarter 2026 financial results, highlighted by a 45% year-over-year increase in total net revenue to $37.8 million. This growth was primarily driven by the commercial performance of MIPLYFFA, which generated $34.0 million in U.S. net revenue, representing a 52% increase compared to the third quarter of 2025. The company achieved profitability this quarter with a net income of $19.2 million ($0.26 per diluted share), a significant turnaround from a net loss in the prior-year period. Management noted that U.S. market penetration for MIPLYFFA has reached approximately two-thirds of the diagnosed patient population within seven quarters of launch, and they anticipate a larger total addressable market than previously estimated. Looking ahead, Zevra plans to submit an sNDA in Q1 2027 to expand the MIPLYFFA label for infants under 24 months. The company maintains a strong liquidity position with $270.9 million in cash and investments, providing flexibility for ongoing R&D and commercial scaling.
Tickers: $ZVRA
Topics: market penetration net income product adoption revenue growth